Speciality: Oncology
Description:
A warm welcome to all the medical professionals joining us for this insightful session on the multifaceted advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies. The landscape of advanced breast cancer treatment has been profoundly reshaped by the advent of CDK4/6 inhibitors. These targeted therapies, including palbociclib, ribociclib, and abemaciclib, have revolutionized the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, demonstrating significant improvements in progression-free and overall survival rates compared to traditional endocrine therapy alone. Their mechanism of action, by selectively inhibiting cyclin-dependent kinases 4 and 6, effectively halts cell cycle progression and offers a more precise approach to combating cancer.
Dr. Bhavna Parikh, a distinguished expert in the field, will delve into the compelling clinical evidence supporting the widespread adoption of these agents. Through landmark clinical trials, CDK4/6 inhibitors have consistently shown superior efficacy, extending the time patients live without disease progression and enhancing their quality of life. This session will explore the nuances of these studies, highlighting the patient populations who benefit most, the optimal sequencing strategies, and the management of potential side effects, ensuring a comprehensive understanding of their practical application in clinical settings.
The integration of CDK4/6 inhibitors into the treatment paradigm for HR+/HER2- advanced breast cancer represents a monumental leap forward in personalized oncology. This webinar is an invaluable opportunity to gain an overall knowledge of the best practices and latest advancements in leveraging these inhibitors for improved patient outcomes. Don't miss this chance to grab the shared knowledge and follow Hidoc for more such interesting webinar sessions that keep you at the forefront of medical innovation.
See More Webinars @ Hidoc Webinars
1.
Belgian Algorithm Reshapes Endometrial Cancer Care
2.
ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer
3.
Nuclear missile workers are contracting cancer: They blame the bases
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Consensus Recommendations for Healthy Hematologic Aging
3.
The Role of Alanine Aminotransferase in Liver Health and Disease
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation